The loss of PTPN2 results in an increase in tumor antigen presentation and T-cell trafficking due to enhanced expression of IFNγ-responsive genes, including MHC-I, Cxcl9, Cxcl10, Cxcl11, and Ccl5 [9]. The gene discussed is CXCL9; the disease is neoplasm.